Protgen Ltd
13
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
Role: lead
Recombinant Human Serum Albumin in Healthy Subjects
Role: lead
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
Role: lead
Phase II/III of Recombinant Human Serum Albumin
Role: lead
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer
Role: lead
Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer
Role: lead
Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Role: lead
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Role: lead
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
Role: lead
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Role: lead
Single-dose Escalation Trial of M2ES in Healthy Volunteer
Role: lead
All 13 trials loaded